Phase 2 trial of neoadjuvant chemotherapy and transoral endoscopic surgery with risk-adapted adjuvant therapy for squamous cell carcinoma of the head and neck.
Jared M WeissJuneko E Grilley-OlsonAllison Mary DealJose P ZevallosBhishamjit S CheraJennifer PaulMary Fleming KnowlesDmitriy UsenkoMark C WeisslerSamip PatelDavid N HayesTrevor HackmanPublished in: Cancer (2018)
The study met both its primary efficacy endpoint and the secondary feasibility endpoint. Neoadjuvant, systemic therapy and surgical resection followed by risk-adapted adjuvant therapy resulted in high response rates and excellent long-term outcomes and should be further studied. Cancer 2018;124:2986-92. © 2018 American Cancer Society.
Keyphrases
- neoadjuvant chemotherapy
- locally advanced
- squamous cell carcinoma
- papillary thyroid
- lymph node
- rectal cancer
- squamous cell
- lymph node metastasis
- sentinel lymph node
- radiation therapy
- mesenchymal stem cells
- atrial fibrillation
- early stage
- coronary artery disease
- young adults
- cell therapy
- replacement therapy
- drug induced